VIR250117C7500
- 1.07
- +0.07+7.00%
Vir Biotechnology Newsroom
Express News | US FDA: Revoked Emergency Use Authorization for GSK and Vir Biotechnology's Sotrovimab as of Dec 13 - Website
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Vir Gets FDA Breakthrough Therapy Status for Two Drugs
Express News | Vir Biotechnology Inc - Phase 3 Eclipse Program to Begin in First Half of 2025
Express News | Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA Prime Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Loss-making Vir Biotechnology (NASDAQ:VIR) Has Seen Earnings and Shareholder Returns Follow the Same Downward Trajectory Over Past -80%
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
JANX Stock Hits Record High on Prostate Cancer Study Data
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday
Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results -- Barrons.com
Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Hold Rating, Maintains Target Price $10
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), PTC Therapeutics (PTCT) and Vir Biotechnology (VIR)
Janux, Vir Stocks Rally on Positive Data for Janux Drug JANX007
Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely?
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN Masked T-Cell Engager Programs
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
J.P. Morgan Sticks to Their Hold Rating for Vir Biotechnology (VIR)